Musely Secures $360M Non-Dilutive Financing to Scale Direct-to-Consumer Telemedicine Platform

Musely just secured over $360M from General Catalyst’s Customer Value Fund, without giving up equity. That is not a funding round. That is financial jiu-jitsu in a hoodie. Under Jack Jia’s leadership, alongside co-founders Carrie Jiao, Ethan Gui, and Rob Bradshaw, Musely built a direct-to-consumer telemedicine platform for skin, hair, and menopause care while the market was busy confusing growth with noise. Cash-flow positive, serving more than 1.2M patients, growing around 50% year over year, the company did not arrive at this moment by accident. It arrived here because the numbers started talking louder than the hype.

The story starts in 2013, back when it was Trusper, a wellness community riding the early wave of social discovery. The signal was hiding in plain sight. Skincare kept surfacing, not as vanity, but as frustration. Consumers were tired of overpriced creams making promises with the confidence of a late-night infomercial and the success rate of a weather app. By 2019, the pivot was surgical. Out went the guesswork. In came prescription-strength, compounded treatments delivered through asynchronous telemedicine, connecting patients directly with board-certified dermatologists and OB-GYNs.

With Dr. Marie Jhin, MD, serving as CMO, Musely leaned into something healthcare systems often struggle to operationalize: accessibility with personalization. Melasma, acne, rosacea, hyperpigmentation, hair loss, menopause symptoms. Real conditions. Real patients. Real treatment plans shipped directly to doors instead of forcing people into another fluorescent waiting room holding a clipboard from 2006.

Then comes General Catalyst with a capital structure that deserves attention. The Customer Value Fund is designed for companies that already understand customer economics. Capital gets deployed against growth performance, tied to revenue generation instead of ownership dilution. No traditional equity trade. No surrendering chunks of the company just to buy more time.

Musely raised $20M back in 2014 and then spent more than a decade avoiding the standard startup pilgrimage of endless dilution rounds and performative fundraising laps. This latest $360M move feels less like fundraising and more like a company cashing in on discipline.

There is a bigger signal buried in this deal. Direct-to-consumer healthcare is brutally expensive to scale because attention is expensive to buy, trust is difficult to earn, and retention exposes every weakness in the product. The companies that survive long enough to matter are usually the ones obsessed with outcomes long before investors become obsessed with multiples.

Musely is betting that personalized care delivered through a screen can move faster than legacy healthcare systems designed around friction. General Catalyst is betting that when a company truly understands its customer engine, preserving ownership matters more than collecting headlines.